| T1895 |
SKLB 610
|
1125780-41-7
|
98%
|
|
|
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, a...
|
| T61304 |
FGFR2-IN-1
|
2677709-76-9
|
98%
|
|
|
FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3 with IC50s of 460, 140, and 2200 nM, respectively.FGFR2-IN-1 can be used for the study of c...
|
| T76877 |
Vofatamab
|
1312305-12-6
|
98%
|
|
|
Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combinatio...
|
| T76673 |
Bemarituzumab
|
1952272-74-0
|
98%
|
Bemarituzumab
|
|
Bemarituzumab is a novel humanized IgG1 monoclonal antibody targeting FGFR2b. Bemarituzumab prevents FGFR2b from binding to FGF and activation. Potential applica...
|
| T76672 |
Aprutumab
|
1634620-63-5
|
98%
|
Aprutumab
|
|
Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize ...
|
| T6154 |
SU11274
|
658084-23-2
|
98%
|
|
|
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
|
| T6036 |
Brivanib
|
649735-46-6
|
98%
|
|
|
Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR...
|
| T8544 |
Masitinib mesylate
|
1048007-93-7
|
98%
|
|
|
Masitinib mesylate (AB-1010 mesylate) is a selective and orally bioavailable c-Kit inhibitor (IC50 of 200 nM,540/800 nM,510 nM for human recombinant c-Kit;PDGFRα...
|
| T13156L |
TG 100572 Hydrochloride
|
867331-64-4
|
98%
|
|
|
TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1...
|
| T1948 |
AZD4547
|
1035270-39-3
|
98%
|
|
|
AZD4547, a new-type specific FGFR inhibitor, targets for FGFR1/2/3 (IC50: 0.2/2.5/1.8 nM in cell-free assays).
|
| T1338 |
Sucralfate
|
54182-58-0
|
|
|
|
Sucralfate (Sucrose octasulfate–aluminum complex) is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active ...
|
| T19355 |
Heparan Sulfate
|
9050-30-0
|
|
|
|
Heparan Sulfate is a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on th...
|
| TQ0317 |
R1530
|
882531-87-5
|
|
|
|
R1530 is a multikinase inhibitor with antineoplastic and antiangiogenesis activities.
|
| T9030 |
SU4984
|
186610-89-9
|
100%
|
|
|
SU4984 is a cell-permeable, ATP-competitive and reversible inhibitor of the fibroblast growth factor receptor 1 (FGFR1).
|
| T7104 |
Dovitinib lactate
|
692737-80-7
|
100%
|
|
|
Dovitinib lactate (TKI-258 lactate)(TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) (IC50 :5 nM).
|
| T2372L |
Ponatinib Hydrochloride
|
1114544-31-8
|
100%
|
|
|
Ponatinib Hydrochloride (AP-24534 Hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.3...
|
| T27319 |
FIIN-4
|
2093088-81-2
|
100%
|
|
|
FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.
|
| T2S0007 |
Ferulic acid sodium
|
24276-84-4
|
100%
|
|
|
Ferulic acid sodium (Sodium ferulic), the sodium salt of ferulic acid, is a drug used in traditional Chinese medicine for treatment of cardiovascular and cerebro...
|
| T6184 |
Orantinib
|
252916-29-3
|
100%
|
|
|
Orantinib (NSC 702827) , a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation. It ...
|
| T15185 |
Lucitanib
|
1058137-23-7
|
96.13%
|
|
|
Lucitanib (E-3810) is a novel VEGFR and FGFR inhibitor. It potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 (IC50s: 7 nM, 25 nM, 10 nM, ...
|
